The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Express News | Altimmune Inc: Weekly Subcutaneous Doses of Pemvidutide Resulted in up to 68.5% Relative Reduction in Liver Fat Content
Express News | Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld) in Journal of Hepatology
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
Better GLP-1 Biotech Stock: Altimmune Vs. Viking Therapeutics
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
Altimmune to Participate at Leerink Partners Therapeutics Forum
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Express News | Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic
Express News | Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune Drops 15% After Sudden Death of Finance Chief